Literature DB >> 717396

Guidelines for protocol studies in chronic lymphocytic leukemia.

R T Silver, A Sawitsky, K Rai, J F Holland, O Glidewell.   

Abstract

The treatment of any malignant disease requires appropriate criteria for diagnosis of the disease, appropriate methods for study, and techniques for evaluating response to treatment. In the past five years, there have been a number of proposed guidelines for studies in chronic lymphocytic leukemia (CLL). These submitted guidelines represent a further re-evaluation of concepts in CLL, and are currently in use by Cancer and Leukemia Group B for protocol studies. It is clear that revisions will continue to be make as new knowledge accumulates. In the meantime, these are submitted for publication for use by other investigators.

Entities:  

Mesh:

Year:  1978        PMID: 717396     DOI: 10.1002/ajh.2830040406

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Risk categories and refractory CLL in the era of chemoimmunotherapy.

Authors:  Thorsten Zenz; John G Gribben; Michael Hallek; Hartmut Döhner; Michael J Keating; Stephan Stilgenbauer
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

2.  Cytokine expression in B-CLL in relation to disease progression and in vitro activation.

Authors:  M Aguilar-Santelises; D Gigliotti; L M Osorio; A D Santiago; H Mellstedt; M Jondal
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

3.  Experimental treatment of chronic lymphocytic leukemia with extracorporeal photochemotherapy. Initial observations.

Authors:  R M Knobler; R Pirker; E M Kokoschka; H Ludwig; W Linkesch; M Micksche
Journal:  Blut       Date:  1990-04

4.  Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria.

Authors:  D R Gandara; C B George; C A Ries; M M Koretz; J P Lewis
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.

Authors:  Tait D Shanafelt; Neil E Kay; Greg Jenkins; Timothy G Call; Clive S Zent; Diane F Jelinek; William G Morice; Justin Boysen; Liam Zakko; Susan Schwager; Susan L Slager; Curtis A Hanson
Journal:  Blood       Date:  2008-11-17       Impact factor: 22.113

6.  Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients.

Authors:  C da Cunha-Bang; J Simonsen; K Rostgaard; C Geisler; H Hjalgrim; C U Niemann
Journal:  Blood Cancer J       Date:  2016-11-11       Impact factor: 11.037

7.  Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.

Authors:  A Olsson; M Norberg; A Okvist; K Derkow; A Choudhury; G Tobin; F Celsing; A Osterborg; R Rosenquist; M Jondal; L M Osorio
Journal:  Br J Cancer       Date:  2007-08-28       Impact factor: 7.640

8.  Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia.

Authors:  Pablo Mozas; Alfredo Rivas-Delgado; Tycho Baumann; Neus Villamor; Valentín Ortiz-Maldonado; Marta Aymerich; Dolors Costa; Alba Navarro; Eva Giné; Armando López-Guillermo; Emili Montserrat; Julio Delgado
Journal:  Blood Cancer J       Date:  2018-01-16       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.